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Abstract
Background: Pulmonary arterial hypertension (PAH) is commonly accompanied with the activation of the
renin-angiotensin-aldosterone system (RAAS). Renal sympathetic denervation (RSD) reduces PAH partly through
the inhibition of RAAS. Analogically, we hypothesized that pulmonary artery denervation (PADN) could reverse
PAH and PAH-induced right ventricular (RV) dysfunction by downregulating the local RAAS activity.
Methods: Twenty-five beagle dogs were randomized into two groups: control group (intra-atrial injection of
N-dimethylacetamide, 3 mg/kg, n = 6) and test group (intra-atrial injection of dehydrogenized-monocrotaline,
3 mg/kg, n = 19). Eight weeks later, dogs in the test group with mean pulmonary arterial pressure (mPAP)
≥25 mmHg (n = 16) were reassigned into the sham (n = 8) and PADN groups (n = 8) by chance. After another
6 weeks, the hemodynamics, pulmonary tissue morphology and the local RAAS expression in lung and right
heart tissue were measured.
Results: PADN reduced the mPAP (25.94 ± 3.67 mmHg vs 33.72 ± 5.76 mmHg, P < 0.05) and the percentage of
medial wall thickness (%MWT) (31.0 ± 2.6 % vs 37.9 ± 2.8 %, P < 0.05) compared with the sham group. PADN
attenuated RV dysfunction, marked with reduced atrial natriuretic peptide (ANP), brain natriuretic peptide
(BNP) and ratio of right ventricular to left ventricular plus septum weight [RV/(LV + S)]. Moreover, the local
RAAS expression was activated in PAH dogs while inhibited after PADN.
Conclusions: PADN improves hemodynamics and relieves RV dysfunction in dogs with PAH, which can be
associated with the downregulating RAAS activity in local tissue.
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Background
Pulmonary arterial hypertension (PAH) is a lethal disease
with poor long-term prognosis and high mortality, which
is defined by a mean pulmonary arterial pressure
(mPAP) ≥25 mmHg at rest [1]. Recent clinical trials
study groups have reported that the mortality rate of
French Registry patients at 3–5 years is approximately
20–30 % and the mortality rate of REVEAL Registry pa-
tients at 1–3 years is in the range of 10–30 % [2]. The
disease is characterized by excessive pulmonary vascular
remodeling, contributing to increased pulmonary vascu-
lar resistance (PVR) and pulmonary pressure [3, 4]. In-
creased pulmonary vascular afterload can result in RV
adaptation, ultimately leading to RV failure and even
death. Besides pressure overload, other factors, such as
oxidative stress, ischemia, inflammation, and neurohor-
monal activation, are also involved in RV remodeling
[5]. Actually, the RV function is a major determinant of
prognosis in PAH patients [6, 7].
Despite the complex and multifactorial pathogenesis
of PAH, neurohormonal activation has been considered
as an important factor in the pathophysiology of PAH.
Two key players of the neurohormonal system are the
sympathetic nervous system (SNS) and the RAAS. It is
well established that sympathetic nerve (SN) activity is
increased in patients with PAH [8, 9], indicating that
hyperactivity of the SNS plays a central role in PAH.
Additionally, the RAAS has been proved to be activated
when PAH occurs both in animal models and clinically
[10–12]. For instance, the increased expression of angio-
tensin converting enzyme (ACE) along with angiotensin II
(Ang II) was observed in the development of pulmonary
hypertension (PH) [10, 11]. Elevation of Ang II type 1 re-
ceptor (AT1 receptor) was also demonstrated in patients
with idiopathic pulmonary arterial hypertension [12]. All
the evidence above has illustrated that SNS and RAAS are
closely involved in the development of PAH, and may have
long-term effects on the progression of PAH.
Pulmonary artery denervation (PADN) is one of the
newest potential therapies of PAH. Performed at the bi-
furcation area of the main pulmonary artery (PA), the
ostial right PA and the ostial left PA, by inducing local
injury or destruction to the baroreceptor or sympathetic
nervous fibers, PADN reduces the pulmonary arterial
pressure [13]. It has been demonstrated that PADN con-
ducted in the main pulmonary artery bifurcation area in-
duces severe SN injury and abolishes PAH induced by
balloon inflations in a dog model [14]. Reduction of
PAH and improvement of right heart function have also
been proved clinically in patients with PAH [13]. However,
the associated mechanisms of PADN remain unclear. Pre-
vious studies have shown that renal sympathetic denerv-
ation (RSD) decreases PAP and RV pressure, mediating
mainly by inhibiting the activity of the RAAS [15, 16].
Based on the aforementioned knowledge, we hypothesized
that PADN may reduce PAH and improve RV function by
modulating the local RAAS activity.
In our study, we sought to investigate whether PADN
can attenuate PAH and PAH-induced RV dysfunction
through downregulating the local RAAS activity.
Methods
Experimental animals
Twenty-five adult beagle dogs (body weight 8 to 10 kg)
were purchased from Nanjing Medical University Animal
Laboratory. They were housed in a room under a 12-h
light–dark cycle at 20 to 24 °C. Food and water were freely
available throughout the experiment. All protocols were
approved by the Institutional Animal Care and Use Com-
mittee, consistent with the Guide for the Care and Use of
Laboratory Animals (National Research Council).
In the study, each dog was assigned with a computer-
generated random number. Then, dogs were allocated
into two groups by chance: control group (n = 6) and
test group (n = 19). Dogs in test group were intra-atrially
injected with dehydrogenized monocrotaline (DHMCT)
at a dose of 3 mg/kg, while the control group received
equal amount of N-dimethylacetamide intra-atrial injec-
tion. Eight weeks later, beagles in test group with
mPAP ≥ 25 mmHg were randomly reassigned into into
sham (n = 8) and PADN (n = 8) groups. PADN catheter
connected with a generator was positioned in the PA.
Ablation procedure was performed for all animals in the
PADN group while the procedure was not performed in
the sham group [17]. At the 14th week, all animals were
sacrificed when all measurements were completed. Pul-
monary and right ventricular tissue was stored stored in
a −80 °C refrigerator for further studies (Fig. 1).
Hemodynamic measurements and PADN Procedure
The methods of hemodynamic measurements and
PADN procedure have been described in previous litera-
ture [13, 14, 17]. Briefly, after stable anesthesia, a 7-F
sheath (Baxter Healthcare Corp.) was inserted percutan-
eously via the femoral vein and a Swan-Ganz catheter
(Edwards Lifesciences, Irvine, California) was positioned
at the distal PA for the measurement of mPAP, pulmon-
ary arterial systolic pressure (PASP), pulmonary arterial
diastolic pressure (PADP), mean right ventricular pres-
sure (mRVP), right ventricular systolic pressure (RVSP),
pulmonary artery occlusion pressure (PAOP) and cardiac
output (CO). Then, the PVR [PVR = (mPAP- PAOP) /
CO] was calculated. Hemodynamic measurements were
tested at three different time points, the beginning of the
experiment, the 8th week and the 14th week, separately.
For PADN procedure, a dedicated 7-F catheter
(PADNTM; Microport Co., Shanghai, China) was ad-
vanced to the main PA along an 8 Fr long sheath, based
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on pulmonary arteriography. This catheter has a tapered
circular tip with 10 pre-mounted electrodes [14]. After
the circular tip was released from the sheath, by ma-
nipulating a rotating handle, it would be positioned at 3
sites,which were the distal main PA, the conjunction
point of the main pulmonary artery trunk lateral wall
and ostial left PA, the ostium of left PA, respectively.
When the electrodes tightly contacted the endovascular
surface, ablation would be performed at 3 sites in turn.
The ablation parameters were: a temperature of 45 to
50 °C, energy ≤ 10 W, time 120 s.
Histological analysis
The samples were excised, fixed in 10 % formalin over-
night and then embedded in paraffin [11]. Paraffin-
embedded tissue was sectioned into 5 μm thick slices
and stained with hematoxylin and eosin (H&E). To
evaluate medial wall thickness in muscularized arteries
with an external diameter of 80 to 120 μm, we calculated
the percentage of medial wall thickness (%MWT), which
was [(external diameter- internal diameter)/external
diameter] × 100 %. At least ten pulmonary arteries per sec-
tion were observed and photographed using an Olympus-
BHS microscope (San Jose, California) attached to a
QImaging Retiga 4000RV digital camera (Surrey, British
Columbia, Canada). Two skilled investigators who had no
knowledge of the group assignment took photographs and
calculating the %MWT, separately.
Western blots
Lung and heart tissues were lysed with a buffer contain-
ing RIPA (Beyotime, China), 10 % phosphatase inhibitor
(Roche Applied Science, Germany) and 1 % proteinase
inhibitor (Sigma, USA). Bicinchoninic acid assay was
used to measure the protein concentration. Equal
amounts of the samples were loaded on 10 % SDS–
PAGE gels. Then, protein was transferred to a PVDF
membrane (Millipore Corporation, USA) and incubated
for 1 h at room temperature in blocking solution (5 %
non-fat milk). The membrane were incubated overnight
at 4 °C in blocking solution containing primary antibodies.
Then, it was washed and incubated with horseradish per-
oxidase conjugated secondary antibody (Cell Signaling
Technology, USA) for 1 h at room temperature. After a
second wash, the membrane was developed using en-
hanced chemiluminescence substrate (Millipore Corpor-
ation, USA). The band intensities were analyzed using
Image J software (National Institutes of Health, Bethesda,
Fig. 1 Study flowchat
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USA). Primary antibodies against renin, Ang II, ACE, min-
eralocorticoid receptor (MR), BNP, phospho-ERK1/2
(Thr202 + Tyr204) and β-actin were purchased from
BIOSS Biotechnology (bs-6184R, bs-0587R, bs-0439R, bs-
1850R, bs-7132R, bs-3016R, bs-0061R). Primary anti-
bodies against Ang II type 2 receptor (AT2 receptor) and
ANP were obtained from Santa Cruz Biotechnology
(sc-9040, sc-18811).
RNA quantitative reverse transcriptase-polymerase chain
reaction analysis (qPCR)
Total RNA was extracted using TRIzol reagent (Invitrogen,
USA). For mRNA expression analysis, total RNA was re-
verse transcribed into cDNA using the PrimeScript RT re-
agent Kit (TakaRa Biotechnology, China), then it was
amplified according to the instructions of the SYBR Premix
Ex Taq kit (TakaRa Biotechnology, China) on an ABI7500
system (Grand Island, NY, USA). In addition, the equation
2-ΔΔCt was used to determine the relative amount of
mRNA in specific target genes. Primer sequences for dog
GAPDH are 5’- AGTGGATATTGTCGCCATCA -3’
(forward) and 5’- CAACATACTCAGCACCAGCA -3’
(reverse), for dog AT1 receptor are 5’- ACTGACTTTGC-
CACTATG -3’ (forward), 5’- ATGATGCAGGT-
GACTTTT -3’ (reverse).
Statistical analysis
SPSS 22.0 (IBM Corporation, Armonk, USA) was used
for statistical analysis. Data were expressed as mean ±
standard deviation (SD). The normality test for all vari-
ables was performed using the Shapiro-Wilk test. For
normally distributed data, the unpaired Student’s t-test
was used for binary comparisons, while one-way
ANOVA was employed for multiple comparisons. For
skewed data distribution, differences in variables were
analyzed using the Wilcoxon signed rank or Friedman
test. P < 0.05 was considered statistically significant.
Results
Animal models and mortality
Monocrotaline-induced PH is a reproducible model of
progressive pulmonary vasculopathy that reasonably
mimics PAH and RV failure [18, 19]. In our study, we
established the experimental PAH model by intra-atrially
injecting DHMCT at the start point of the research
(week 0). Eight weeks later, the successful establishment
of PAH model was evaluated by medial wall thickening
and the increased mPAP. As a result, sixteen dogs in the
test group were successfully established and included in
the further study, leaving three dogs excluded. At the
14th week, two dogs in the sham group and one dog in
the PADN group died, leaving six dogs in sham group
and seven dogs in the PADN group.
Hemodynamics and RV function after PADN
The hemodynamic data of three time points (week 0,
week 8 and week 14) among the three groups were
shown in Table 1. There was no significant difference in
the baseline hemodynamic parameters among the three
groups. At the 8th week, an elevation of mPAP was ob-
served in test group compared with control group
(28.64 ± 4.22 mmHg vs 16.87 ± 1.66 mmHg, P < 0.05), as
well as increased PADP, PASP and PVR in test group,
which revealed that the PAH model was successfully
Table 1 Changes in the hemodynamic parameters in three
groups






















































































































Values are mean ± SD. *P < 0.05 compared with the control group. **P < 0.05
compared with the control group. *** P < 0.05 compared with value at week
14. ****P < 0.05 compared with the sham group
PVR pulmonary vessel resistance, mPAP mean pulmonary arterial pressure,
PADP pulmonary arterial diastolic pressure, PASP pulmonary arterial systolic
pressure, mRVP mean right ventricular pressure, RVSP right ventricular systolic
pressure, PAOP pulmonary artery occlusion pressure, CO cardiac output
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established. In the PADN group, mPAP, PVR, PADP and
PASP were significantly reduced compared with sham
group (Table 1, Fig. 2a to d). However, heart rate and
PAOP did not show significant changes among the three
groups. Taken together, we believed that PADN can re-
lieve monocrotaline-induced PAH.
The RV function was evaluated from three aspects.
First, in hemodynamics, despite CO among the three
groups didn’t show significant difference, the mRVP and
the RVSP increased in sham group compared with control
group. After PADN, these values decreased compared to
sham group (Table 1, Fig. 2e and f). Then, RV/(LV + S), a
hallmark of RV function, was calculated and found to in-
crease in dogs with PAH while reduce after PADN oper-
ation (Fig. 2g). Thirdly, as markers of myocardial stress,
the levels of ANP and BNP are correlated with myocardial
dysfunction and BNP provides prognostic information for
PAH diagnosis and follow-up assessments [1]. Thus, levels
of ANP and BNP in right ventricles (RV) of the dogs were
tested in the study. As presented in Fig. 2h, the levels of
ANP and BNP in the right ventricular tissue were higher
in sham group with PAH induction than in control group,
Fig. 2 Hemodynamic parameters and RV function in three groups. PADN reversed the development of PAH, demonstrated by the decrease of
mPAP (a), PVR (b), PADP (c) and PASP (d). Meanwhile, PADN improved RV function, demonstrated by reduced mRVP (e), RVSP (f), RV/(LV + S) (g),
ANP and BNP (h). # P < 0.05 compared with the control group in week 8. ‖P < 0.05 compared with the control group in week 8. $ P < 0.05
compared with the control group in week 14. & P < 0.05 compared with the control group in week 14. * P < 0.05 compared with the PADN
group in week 14. ×P < 0.05 compared with the sham group in week 14. ÷ P < 0.05 compared to the control group. ∞P < 0.05 compared to the
sham group
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representing RV dysfunction caused by PAH. However,
the levels of ANP and BNP were decreased in dogs per-
formed with PADN, which indicate that PADN can ameli-
orate the RV function in dogs with PAH.
These results above showed that the PADN procedure
led to improvements in hemodynamics and RV function
in an experimental PAH model.
PA remodeling
Figure 3a showed the representative pictures of
hematoxylin and eosin–stained lung sections obtained
from dogs in three groups. Pulmonary vessel thickening
and luminal stenosis owing to muscularization were ob-
served in the sham group compared with the control
and PADN groups. The %MWT, a marker of pulmonary
arterial remodeling, was also calculated (Fig. 3b). In the
sham group, the %MWT increased (sham group, 37.85 ±
2.80 % vs control group, 29.54 ± 1.85 %; P < 0.05). After
PADN, it was 33.04 ± 4.41 %, significantly lower than that
in the sham group. These data demonstrated that PADN
could ameliorate pulmonary vascular remodeling.
Effects of PADN on the RAAS activity in lung tissue
Main components of the RAAS in lung tissue, namely,
renin, ACE, Ang II, AT2 receptor and MR, were tested
by Western blotting. Real-time PCR was used in detect-
ing AT1 receptor messenger RNA (mRNA). DHMCT-
injection was characterized by overexpression of renin,
ACE, Ang II, AT2 receptor and MR. PCR results showed
a more than threefold increase of AT1 receptor mRNA
in lung sections in the DHMCT-injected dogs as
compared to the dogs from the control group. PADN
treatment in dogs significantly decreased the expression
of the mentioned proteins observed in sham group as
well as the transcription of AT1 receptor in the PADN
group. The results implied that PADN could partially re-
verse the DHMCT-induced RAAS overexpression in
lung tissue (Fig. 4).
Effects of PADN on the RAAS activity in the right heart
In the study, we also tested the transcription and expres-
sion of RAAS in the right heart tissue of the above three
groups. Injection of DHMCT in dogs resulted in an ob-
vious increase in the transcription and expression of
RAAS, which paralleled with the results in lung tissue.
In contrast, the transcription and expression went down
for PADN group (Fig. 5). The results indicate that PADN
can inhibit the local RAAS in cardiac tissue.
Effects of PADN on signaling of the AT1 receptor
As mentioned above, the mRNA of AT1 receptor was
observed to decrease in dogs with RV dysfunction after
PADN operation. To test whether the observed decrease
in AT1 receptor resulted in decreased receptor signaling,
we dectected the ERK1/2 activity, one downstream tar-
get of AT1 receptor [20, 21], also an important regulator
of cell proliferation. As shown in Fig. 6, ERK1/2 activity
(phosphorylated ERK1/2) was significantly increased in
dogs with DHMCT injection (sham group). Phosphory-
lated ERK1/2 was obviously reduced in PADN group in
comparison with sham group both in pulmonay (Fig. 6a)
and right ventricular tissue (Fig. 6b). Thus, we found
Fig. 3 PA remodeling. PADN ameliorated pulmonary arterial remodeling. a Representative morphologic images of pulmonary arterial structure in
different groups. Sections were stained with hematoxylin and eosin (×200). b Bar diagram showed the difference of the %MWT in different
groups . #P < 0.05 compared with the control group. *P < 0.05 compared to the sham group
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Fig. 4 Influence of PADN on the pulmonary RAAS activity. PADN inhibited the local RAAS activity in lung tissue. a Representative western blot
images of renin, ACE, AngII, AT2, MR and β-actin in pulmonary tissue. b–d Bar diagram showed intensity data of western blot images, all data
were normalized by β-actin. e Bar diagram showed data of mRNA expression of AT1 receptor in three groups. C1, C2, C3 : contol group; S1, S2,
S3 : sham group; P1, P2, P3 : PADN group. *P < 0.05 compared to the control group. #P < 0.05 compared to the sham group
Fig. 5 Influence of PADN on the cardiac RAAS activity. PADN reversed RAAS expression in the right heart. a Representative western blot images
of renin, ACE, AngII, AT2, MR and β-actin in right heart. b–d Bar diagram showed intensity data of western blot images, all data were normalized
by β-actin. e Bar diagram showed data of mRNA expression of AT1 receptor in different groups. C1, C2, C3 : contol group; S1, S2, S3 : sham group;
P1, P2, P3 : PADN group. *P < 0.05 compared to the control group. #P < 0.05 compared to the sham group
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protein levels of phosphorylated ERK1/2 showed the
same results as the mRNA of AT1 receptor. All these
findings together suggest that the AT1 receptor expres-
sion and signaling are decreased in dogs with PAH after
PADN.
Discusion
Our study not only explored the impact of PADN on
pulmonary vascular remodeling and RV dysfunction, but
also investigated the change of RAAS activity after
PADN. We provided evidence: a) that PADN attenuated
the PAH induced by DHMCT treatment in the beagles,
as evidenced by the absence of a significant increase in
mPAP and pulmonary vascular wall thickness, b) that
PADN treatment improved RV function marked by re-
duction of the ANP, BNP and RV/(LV + S) elevation
caused by DHMCT injection, and c) the local RAAS ac-
tivity both in lung and right heart was activated in the
pathogenesis of PAH, while it was inactivated after
PADN operation. Thus, our results suggest that down-
regulation of the local RAAS activity may be associated
with the improvement of abnormal hemodynamics and
RV dysfunction by PADN.
As is widely known, the primary function of the RAAS
is to regulate intravascular volume to maintain blood
pressure [22]. The prevailing evidence suggests that
RAAS activity is mainly controlled by the renin, which
cleaves angiotensinogen to Ang I. Ang I is hydrolyzed to
Ang II by ACE. Then, Ang II, an important role in the
development of PAH [23], binds to both the AT1 and
AT2 receptors. AngII binds to the AT1 receptor to pro-
mote the growth of pulmnary artery smooth muscle cells
and stimulate aldosterone synthesis. Aldosterone increases
vascular endothelial and smooth muscle cell oxidant
stress, which has been implicated in the pathogenesis of
PAH [22]. Patients with PAH often have a low cardiac out-
put, to compensate, the RAAS is up-regulated in the
pathogenesis of PAH and RV hypertrophy [23–26]. A lot
of drugs, such as renin inhibitors, ACE inhibitors and AT1
receptor antagonists, aiming at interfering with the RAAS
signaling have been put into wide clinical administration
for PAH treatment [27]. Besides the experimental studies,
some clinical studies have also revealed similar
phenomenon of up-regulation in local pulmonary RAAS
activity for patients with iPAH [12, 28], which implies that
activated RAAS may be a common mechanism of PAH
sharing in mammals.
PADN is a new treatment for PAH based on the oper-
ation of SNS [13]. The therapeutic effects of PADN on
PAH in patients [13] and experimental models [14, 17]
have been reported and accepted. However, for existing
experimental and clinical researches, little has been done
to explore the influence of PADN operation on local
RAAS, as well as its corresponding connection with
PAH and RV dysfunction.
Since the RAAS is modulated by the sympathetic adren-
ergic nervous system, it is now well accepted that the SNS
has a close relationship with the RAAS activity. Evidence
has revealed the role for the SNS in the modulation of
RAAS in producing and maintaining renovascular hyper-
tension [29]. It has been found in patients with PAH, sys-
temic RAAS activity is upregulated, based on findings of
upregulated SNS activity [15]. Since PADN induces severe
SN injury and abolishes PAH [14], we hypothesized that
the SN injury induced by PADN may influence the local
RAAS activity and therefore act protectively to pathogen-
esis of PAH and RV dysfunction.
In our study, we did find a significant increase in renin,
Ang II and ACE, which was the same for AT1 receptor,
AT2 receptor and MR expression in the pulmonary and
Fig. 6 Influence of PADN on the ERK1/2 activity in lung and right heart. ERK1/2 activity was inhibited after PADN. Western blotting analysis for
p-ERK1/2 in pulmonary tissue (a) and right ventricular tissue (b). p-ERK1/2 : phosphorylated form of ERK1/2, C1, C2, C3 : contol group; S1, S2, S3 :
sham group; P1, P2, P3 : PADN group. *P < 0.05 compared to the control group. #P < 0.05 compared to the sham group
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right ventricular tissue, acompanied with thickening of the
vascular wall and altering of hemodynamic parameters in-
dicating PAH and RV dysfunction. We also tested one
downstream tyrosine kinases of the AT1 receptor, phos-
phorylated ERK1/2. It was observed that phosphorylation
of ERK1/2 was increased both in pulmonary and cardiac
tissues of dogs with PAH. Consistent with previous inves-
tigations, our results showed that local RAAS activity was
activated in PAH and RV dysfunction.
In accordance with previous investigations [13, 17],
our study showed that the PADN treatment effectively
suppressesed PA medial wall thickening and improved
hemodynamics. What’s more, PADN improved right
ventricular function, which was marked with a signifi-
cant decrease of ANP, BNP and RV/(LV + S). Meanwhile,
PA wall thickness in dogs with PAH was significantly re-
versed, which could explain the reduction in RV after-
load and improvement of RV performance by PADN.
Futhermore, to explore the role of RAAS both in the
pathogenesis of PAH and after PADN procedure, we also
evaluated the local RAAS activity in dogs after PADN.
As a result, a significant decrease in the main compo-
nents of local RAAS in both lung and right heart was
observed, implying that the decrease of local RAAS ac-
tivity may have a relationship with PADN operation.
Moreover, p-ERK1/2 expression, which was a down-
stream mediator of AT1 receptor, was also decreased
after PADN. Taken together, these data above suggest
that PADN ameliorate s pulmonary arterial remodeling
and improves right ventricular function. What’s more,
the phenomenon can be related to the inhibited local
RAAS activity in pulmonary and cardiac tissue. The ef-
fect may be based on the SN injury by PADN procedure.
However, there are some limitations in our study. First,
several methods are available to establish a PH model in
living animals [30]. Whether regulation of local RAAS is
effective in other animal models is an interesting ques-
tion for future investigation. Next, the mechanism for
PADN to treat PAH is complex. Although our work
showed that local RAAS was inhibited after PADN, the
results could not exclude the involvements of other mole-
cules participating in regulating the RAAS activity either
directly or indirectly. Finally, the change of RAAS activity
is a continuous process after PADN, but we only mea-
sured local RAAS activity in dogs at the time point of
6 weeks after PADN. In brief, further experiments should
be done to record the dynamic changes of both the local
RAAS and some other associated indicators to reveal the
complex mechanisms in the process after PADN.
Conclusions
Our results demonstrate that PADN treatment attenuates
thickening of pulmonary vessels and improves RV func-
tion, and this effect is associated with the downregulation
of of the local RAAS activity. Hopefully, our study would
help better understand the mechanisms of improvements
of PA remodeling and cardiac function reversing by
PADN.
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